Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab

INTRODUCTION: Durvalumab after concurrent chemoradiation (cCRT) is now standard of care for unresected stage III non–small cell lung cancer (NSCLC). However, there is limited data on radiation pneumonitis (RP) with this regimen. Therefore, we assessed RP and evaluated previously validated toxicity m...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Med
Auteurs principaux: Shaverdian, Narek, Thor, Maria, Shepherd, Annemarie F., Offin, Michael D., Jackson, Andrew, Wu, Abraham J., Gelblum, Daphna Y., Yorke, Ellen D., Simone, Charles B., Chaft, Jamie E., Hellmann, Matthew D., Gomez, Daniel R., Rimner, Andreas, Deasy, Joseph O.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Clinical Cancer Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7333832/
https://ncbi.nlm.nih.gov/pubmed/32372571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3113
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires